{
  "chapter": "Respiratory Pharmacology-Respiratory Pharmacology",
  "questions": [
    {
      "q_no": 1,
      "question": "A 12-year-old girl with a known history of cystic fibrosis (CF) presents with a persistent cough and increased sputum production over the past two weeks. Her pulmonary function tests show a significant decline in FEV1 compared to her baseline. Sputum culture reveals Pseudomonas aeruginosa. She has been compliant with her routine medications, including a CFTR modulator, mucolytics, and pancreatic enzyme replacement therapy. Which of the following pharmacological adjustments is the most appropriate next step in managing this patient's current clinical condition?",
      "options": {
        "A": "Add inhaled tobramycin to her current regimen",
        "B": "Switch her CFTR modulator to a different one",
        "C": "Increase the dose of her mucolytic agent",
        "D": "Start intravenous ceftazidime and tobramycin"
      },
      "correct_answer": "D",
      "explanation": "Correct Answer: D) Start intravenous ceftazidime and tobramycin Explanation: Here, the significant decline in pulmonary function and the presence of Pseudomonas aeruginosa suggest a severe exacerbation that likely requires intravenous antibiotics for effective management. Intravenous antibiotics, such as ceftazidime and tobramycin, are used for severe or refractory infections. Inhaled tobramycin specifically targets Pseudomonas aeruginosa in the lungs and is effective in treating pulmonary exacerbations in CF patients. This can be a suitable option if the exacerbation is not severe ( Option A). Changing the CFTR modulator might be considered for long-term management if her current one is ineffective, but it is not an immediate intervention for acute exacerbation due to Pseudomonas infection ( Option B). Increasing mucolytic dosage may help in mucus clearance but is not a targeted approach for a Pseudomonas infection ( Option C). Reference: Pulmonary Exacerbations Clinical Care Guidelines | Cystic Fibrosis Foundation",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Respiratory Pharmacology-Respiratory Pharmacology"
    },
    {
      "q_no": 2,
      "question": "Which of the following statements is false regarding the mechanism of action of theophylline?",
      "options": {
        "A": "Inhibit phosphodiesterase 4",
        "B": "Block A1 receptors",
        "C": "Activation of NF kappa B",
        "D": "Cause histone acetylation"
      },
      "correct_answer": "C",
      "explanation": "Correct Answer: C) Activation of NF kappa B Explanation: Theophylline acts by inhibiting the NF kappa B rather than activating it. Mechanism of action of Theophylline: Mnemonic- PANCHI P- P hosphodiesterase 4 inhibitor (Option A) Inhibition of PDEs, © increased cellular cAMP and cyclic GMP levels © Bronchodilation Important PDE isoenzymes in smooth muscle relaxation include PDE3(primary action), PDE4, and PDE5. A - Blocks A denosine (A1) receptor (Option B) Adenosine induces bronchoconstriction in asthmatic patients by releasing histamine and leukotrienes. Theophylline acts as an antagonist to adenosine receptors © bronchodilation. Blocking adenosine A1 receptors might lead to serious side effects, such as cardiac arrhythmias and seizures. N - Inhibit N F kappa B Theophylline inhibits the movement of the proinflammatory transcription factor NF- κ B into the nucleus © reducing the expression of inflammatory genes in asthma and COPD. C- C alcium channel blockade H - Causes H istone acetylation (Option D) © Decrease the inflammatory activity of IL-5, IL-4. I- Reduces the I nflammation. Reference: Goodman and Gilman Pharmacological Basis of Therapeutics, 14th Edition, Page 883",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Respiratory Pharmacology-Respiratory Pharmacology"
    },
    {
      "q_no": 3,
      "question": "A 45-year-old female patient presents with progressive dyspnea on exertion and fatigue. She has a history of systemic sclerosis and is diagnosed with pulmonary arterial hypertension (PAH) based on right heart catheterization, which shows elevated pulmonary arterial pressures. The patient is initiated on inhaled nitric oxide (NO) therapy as part of her treatment plan. Which of the following statements best describes the mechanism by which inhaled nitric oxide improves her symptoms? inflammation and fibrosis. alleviating right ventricular strain. remodeling and reducing hypertension.",
      "options": {
        "A": "Nitric oxide acts by increasing systemic blood pressure, thereby the workload on the left ventricle",
        "B": "Nitric oxide decreases the production of inflammatory cytokines, thereby reducing pulmonary artery",
        "C": "Nitric oxide causes selective pulmonary vasodilation, decreasing pulmonary vascular resistance and",
        "D": "Nitric oxide increases the proliferation of endothelial cells in pulmonary arteries, promoting vascular"
      },
      "correct_answer": "C",
      "explanation": "vascular resistance and alleviating right ventricular strain. Correct Answer: C) Nitric oxide causes selective pulmonary vasodilation, decreasing pulmonary vascular resistance and alleviating right ventricular strain. Explanation: Inhaled nitric oxide acts as a selective pulmonary vasodilator , which helps to reduce pulmonary vascular resistance. This reduction in resistance lowers the pressure in the pulmonary arteries, thereby decreasing the afterload on the right ventricle. This is crucial in PAH, where increased pulmonary pressures can lead to right ventricular hypertrophy and failure. By decreasing this strain, nitric oxide improves the patient's symptoms and cardiac function. Role of Nitric Oxide in PAH: Nitric oxide administered via inhalation does not significantly affect systemic blood pressure; its primary action is localized to the pulmonary vasculature ( Option A). While nitric oxide may have some anti-inflammatory effects, its primary role in PAH is through vasodilation rather than reducing inflammation and fibrosis ( Option B). Nitric oxide does not increase endothelial cell proliferation in a way that promotes beneficial vascular remodeling; its therapeutic effect is mainly through vasodilation of the pulmonary arteries ( Option D).",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Respiratory Pharmacology-Respiratory Pharmacology"
    },
    {
      "q_no": 4,
      "question": "A 45-year-old female patient with a history of asthma and nasal polyps presents with wheezing, shortness of breath, and chest tightness. She reports that her symptoms began shortly after taking aspirin for a headache. On examination, she has diffuse wheezing and reduced breath sounds bilaterally. She is given supplemental oxygen, and nebulized bronchodilators are started. What is the mechanism through which aspirin is producing above symptoms ?",
      "options": {
        "A": "Inhibition of cyclooxygenase-1 (COX-1) leading to increased leukotriene production",
        "B": "Direct stimulation of the beta-2 adrenergic receptors causing bronchoconstriction",
        "C": "Inhibition of lipoxygenase leading to decreased leukotriene production",
        "D": "Blocking of the muscarinic receptors in the bronchial smooth muscle"
      },
      "correct_answer": "A",
      "explanation": "production Correct Answer: A) Inhibition of cyclooxygenase-1 (COX-1) leading to increased leukotriene production Explanation: Based on the history and Clinical findings, the patient developed aspirin-induced asthma, which is primarily due to the inhibition of the COX-1 enzyme. This inhibition reduces the production of prostaglandins, which are protective in the airways, and shifts the arachidonic acid metabolism toward the lipoxygenase pathway, leading to increased production of leukotrienes. Leukotrienes are potent bronchoconstrictors and contribute to the symptoms of asthma. Beta-2 adrenergic receptors , when stimulated, cause bronchodilation , not bronchoconstriction. Beta-2 agonists are used as bronchodilators in asthma treatment ( Option B). Inhibition of lipoxygenase would decrease leukotriene production , leading to bronchodilation and relief from asthma symptoms, which is the opposite of what occurs in aspirin-induced asthma ( Option C). Blocking muscarinic receptors in the bronchial smooth muscle would lead to bronchodilation , not bronchoconstriction. Muscarinic antagonists are used as bronchodilators in the treatment of chronic obstructive pulmonary disease (COPD) and asthma ( Option D).",
      "image": null,
      "explanation_image": "https://raw.githubusercontent.com/tk22kalal/mcqimage/main/pxpharmacology/Respiratory_Pharmacology-Respiratory_Pharmacology_Q4_exp.jpg",
      "chapter_heading": "Respiratory Pharmacology-Respiratory Pharmacology"
    },
    {
      "q_no": 5,
      "question": "During a diagnostic workup for a patient presenting with symptoms of suspected pulmonary arterial hypertension (PAH), a vaso-reactive testing procedure is planned. The patient undergoes right heart catheterization, and baseline hemodynamic measurements are recorded. Subsequently, a vasoactive medication is administered directly into the pulmonary circulation through the catheter. What outcome of vaso-reactive testing in PAH would indicate a positive response?",
      "options": {
        "A": "A positive response indicates a decrease in mean pulmonary artery pressure of at least 10 mmHg",
        "B": "A positive response indicates a reduction in pulmonary vascular resistance of at least 10%",
        "C": "A negative response indicates a favourable response to vasodilator medications.",
        "D": "Calcium channel blockers are contraindicated in positive responders."
      },
      "correct_answer": "A",
      "explanation": "at least 10 mmHg Correct Answer: A) A positive response indicates a decrease in mean pulmonary artery pressure of at least 10 mmHg Explanation: A positive response during vasoactive testing indicates a decrease in mean pulmonary artery pressure of at least 10 mmHg or a reduction in pulmonary vascular resistance of at least 20%. (Option B) Vaso-reactive testing assesses pulmonary vascular response to vasodilators in PAH. It involves right heart catheterization to measure baseline pulmonary artery pressure and vascular resistance. Vasodilators are then administered directly into the pulmonary circulation. Hemodynamic measurements are repeated post-administration to evaluate the response. Vasoactive testing: A negative response indicates non-reactivity to the vasoactive drug ( Option C) Positive responders are actually considered for long-term calcium blocker therapy ( Option D). Reference: Harrison’s Principles of Internal Medicine, 21st Edition, Page 2124 https://pubmed.ncbi.nlm.nih.gov/35261697/ https://www.sciencedirect.com/science/article/abs/pii/S1537189105001205",
      "image": null,
      "explanation_image": "https://raw.githubusercontent.com/tk22kalal/mcqimage/main/pxpharmacology/Respiratory_Pharmacology-Respiratory_Pharmacology_Q5_exp.jpg",
      "chapter_heading": "Respiratory Pharmacology-Respiratory Pharmacology"
    },
    {
      "q_no": 6,
      "question": "A 45-year-old female presents to the cardiology clinic with complaints of increasing shortness of breath. She was diagnosed with pulmonary artery hypertension. Which of the following correctly describes the mechanism of action with respect to the drug? Drug Mechanism of Action 1. Bosentan A. Prostaglandin I-2 agonist 2. Selexipag B. Prostacyclin (PGI-2) analogue 3. Riociguat C. Endothelin receptor antagonist 4. Epoprostenol D. Soluble guanylate cyclase stimulator",
      "options": {
        "A": "1-C, 2-A, 3-D, 4-B",
        "B": "1-B, 2-D, 3-C, 4-A",
        "C": "1-D, 2-B, 3-A, 4-C",
        "D": "1-A, 2-C, 3-B, 4-D"
      },
      "correct_answer": "A",
      "explanation": "Correct Answer: A) 1-C, 2-A, 3-D, 4-B Explanation: The drugs used in PAH are as follows: Mnemonic : PEPSI Coca Cola Mechanism of action Drugs PDE 5 Inhibitors Sildenafil (Viagra), Tadalafil Endothelin Receptor Antagonists Bosentan, Sitaxsentan, Ambrisentan PG-I2 Analogs Treprostinil, Iloprost, Epoprostenol Soluble Guanylyl Cyclase Activators Riociguat I-2 prostaglandin agonist Selexipag Continuous NO Inhalation Nitric oxide Calcium Channel Blockers Amlodipine, Nifedipine Reference: Goodman and Gilman Pharmacological Basis of therapeutics, 14th Edition, Page 696",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Respiratory Pharmacology-Respiratory Pharmacology"
    },
    {
      "q_no": 7,
      "question": "Which of the following best describes the role of corticosteroids in asthma management? administration route varying by use case.",
      "options": {
        "A": "Corticosteroids are bronchodilators",
        "B": "Corticosteroids are only used for severe asthma attacks.",
        "C": "Corticosteroids are limited to maintenance therapy for chronic asthma.",
        "D": "Corticosteroids are used in both acute exacerbations and chronic management of asthma, with their"
      },
      "correct_answer": "D",
      "explanation": "of asthma, with their administration route varying by use case. Correct Answer : D) Corticosteroids play a critical role in both acute exacerbations and chronic management of asthma, with their administration route varying by use case. Explanation: Corticosteroids are integral to both acute and chronic asthma management. Inhaled corticosteroids are used in long-term maintenance therapy for chronic asthma, helping to control persistent inflammation. For acute exacerbations which are not controlled by inhalational corticosteroids and bronchodilators, systemic corticosteroids (oral or IV) are used to rapidly reduce inflammation despite the fact that corticosteroids are not bronchodilators. Route Examples with use Inhalational Corticosteroids DOC- Chronic or persistent asthma Eg: Beclomethasone Fluticasone-Most Potent Mometasone Triamcinolone Budesonide- Most commonly used Ciclesonide Oral Corticosteroids Recommended for refractory asthma Eg: Prednisolone IV Corticosteroids Recommended for status asthmaticus Eg: Hydrocortisone Dexamethasone Reference: KD Tripathi Essentials of Medical Pharmacology, 8th Edition, Page 249-252",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Respiratory Pharmacology-Respiratory Pharmacology"
    },
    {
      "q_no": 8,
      "question": "A 12-year-old child with a history of asthma presents with symptoms of coughing, wheezing, and shortness of breath, particularly during physical activities. The child has been using a short-acting beta-agonist inhaler as needed but continues to experience frequent asthma symptoms. The physician decides to add a medication that does not cause bronchodilation but restricts the inflammatory mediators implicated in asthma. Which medication is being referred to in this scenario?",
      "options": {
        "A": "Sodium cromoglycate",
        "B": "Salmeterol",
        "C": "Magnesium sulfate",
        "D": "Theophylline"
      },
      "correct_answer": "A",
      "explanation": "Correct Answer: A) Sodium cromoglycate Explanation: Sodium cromoglycate is a mast cell stabilizer that inhibits degranulation of mast cells (as well as other inflammatory cells). Release of mediators of asthma-like histamine, LTs, PAF, interleukins, etc. is restricted. It does not cause bronchodilation. Salmeterol (Option B) is a beta 2 sympathomimetic that causes bronchodilation and relieves symptoms of asthma Magnesium sulfate (Option C) blocks calcium channels which leads to bronchodilation. It may be used in acute exacerbations of asthma but not for long-term management. Theophylline (Option D) inhibits PDE3 and PDE 4, resulting in high cAMP levels inside smooth muscle cells resulting in bronchodilation. Reference: KD Tripathi Essentials of pharmacology, 8 th Edition, Page 249",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Respiratory Pharmacology-Respiratory Pharmacology"
    },
    {
      "q_no": 9,
      "question": "A 45-year-old female with a history of asthma presents with acute shortness of breath and wheezing. Despite initial treatment with inhaled bronchodilators and systemic corticosteroids, her symptoms persist. Which of the following can be used to manage this presentation?",
      "options": {
        "A": "Magnesium sulfate",
        "B": "N-acetylcysteine",
        "C": "Bromhexine",
        "D": "Montelukast"
      },
      "correct_answer": "A",
      "explanation": "Correct Answer: A) Magnesium sulfate Explanation : Magnesium sulfate blocks calcium channels, which leads to bronchodilation. Therefore, it may be used in asthma attacks unresolved by administration of other drugs. Mnemonic for the uses of magnesium sulfate: TABLETS Torsades De Pointes (DOC for arrhythmia) Antacid (Magnesium hydroxide) Barium poisoning and Calcium poisoning antidote Laxative effect (Treatment of constipation) Eclampsia (Drug of choice) Tocolytic agent (Relaxes the uterus) Status asthmaticus N-acetylcysteine (Option B) & bromhexine (Option C) are mucolytic agents used to thin mucus secretions. Both drugs do not have a role in treating severe asthma exacerbations. Montelukast (Option D) is a leukotriene receptor antagonist used for long-term asthma management. It is not used for acute exacerbations because it does not provide rapid relief of bronchospasm. Reference: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10420062/",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Respiratory Pharmacology-Respiratory Pharmacology"
    },
    {
      "q_no": 10,
      "question": "A 65-year-old male with a history of COPD on medication presented to the ER with complaints of headache and chest pain. His ECG showed ventricular arrhythmia, and he subsequently experienced a seizure. He had recently begun taking the anti-gout medication allopurinol. What medication is he likely using for COPD?",
      "options": {
        "A": "Theophylline",
        "B": "Albuterol",
        "C": "Ipratropium",
        "D": "Fluticasone"
      },
      "correct_answer": "A",
      "explanation": "Correct Answer: A) Theophylline Explanation : Theophylline has a narrow therapeutic index. It is metabolized by the CYP1A2 enzyme. Thus, enzyme inhibitors (eg. allopurinol) increase blood levels of theophylline causing toxicity. Drugs reducing the effect of theophylline Drugs increasing the effect of theophylline CYP enzyme inducers Drugs include Griseofulvin Phenobarbitone Phenytoin Rifampicin Smoking and alcohol CYP inhibitors Drugs include Ciprofloxacin Omeprazole Cimetidine Allopurinol Erythromycin Reference: KD Tripathi Essentials of Medical Pharmacology, 8th Edition, Page 246",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Respiratory Pharmacology-Respiratory Pharmacology"
    },
    {
      "q_no": 11,
      "question": "A 60-year-old patient has symptoms of a productive cough and difficulty clearing thick mucus from their airways. The patient has a history of COPD and frequently experiences episodes of breathing difficulties. Which of the following drugs can be used to reduce the viscosity of the mucus, thus increasing its clearance in this patient?",
      "options": {
        "A": "Albuterol",
        "B": "Dextromethorphan",
        "C": "Bromhexine",
        "D": "Guaifenesin"
      },
      "correct_answer": "C",
      "explanation": "Correct Answer: C) Bromhexine Explanation: Bromhexine is a mucolytic agent that helps to break down and reduce the viscosity of mucus, facilitating its removal by coughing. This action can be beneficial in conditions like COPD, where mucus plugs can obstruct airways and exacerbate breathing difficulties. Albuterol (Option A) is a bronchodilator. Dextromethorphan (Option B) is an antitussive. Guaifenesin (Option D) is a mucokinetic. None of these directly address the need to reduce mucus viscosity and enhance mucus clearance through coughing. Reference: KD Tripathi Essentials of Medical Pharmacology, 8th Edition, Page 238",
      "image": null,
      "explanation_image": "https://raw.githubusercontent.com/tk22kalal/mcqimage/main/pxpharmacology/Respiratory_Pharmacology-Respiratory_Pharmacology_Q11_exp.jpg",
      "chapter_heading": "Respiratory Pharmacology-Respiratory Pharmacology"
    },
    {
      "q_no": 12,
      "question": "A 65-year-old male with a long history of chronic obstructive pulmonary disease (COPD) is prescribed an anticholinergic to help manage his symptoms. At his follow-up appointment, he reports experiencing increased shortness of breath and wheezing shortly after using his inhaler. Which of the following causes paradoxical bronchoconstriction?",
      "options": {
        "A": "Tiotropium",
        "B": "Ipratropium",
        "C": "Oxitropium",
        "D": "Umeclidinium"
      },
      "correct_answer": "B",
      "explanation": "Correct Answer: B) Ipratropium Explanation: The occurrence of wheezing and increased shortness of breath after using inhaled anticholinergic in a patient with COPD suggests paradoxical bronchoconstriction. Ipratropium bromide can result in such a presentation. Mechanism of Bronchoconstriction: Nebulizer: Due to hypotonic solution and antibacterial additives (benzalkonium chloride, EDTA) Metered-dose inhaler (MDI): Possible due to blockade of prejunctional M2 receptors, increasing ACh release Tiotropium bromide and other LAMAs have no similar reports of paradoxical bronchoconstriction ( Option A, C & D). Reference: Goodman and Gilman Pharmacological Basis of Therapeutics, 14th Edition, Page 882",
      "image": null,
      "explanation_image": "https://raw.githubusercontent.com/tk22kalal/mcqimage/main/pxpharmacology/Respiratory_Pharmacology-Respiratory_Pharmacology_Q12_exp.png",
      "chapter_heading": "Respiratory Pharmacology-Respiratory Pharmacology"
    },
    {
      "q_no": 13,
      "question": "A 68-year-old male with a history of chronic obstructive pulmonary disease (COPD) presents to the clinic for a routine follow-up. He reports experiencing increased shortness of breath and wheezing, particularly during physical activity. He is on albuterol used as needed, and the physician decides to add ipratropium. Which of the following is the mechanism of action of the latter? A. I 2 receptor agonist",
      "options": {
        "B": "M2 receptor agonist",
        "C": "M2 receptor antagonist",
        "D": "M3 receptor antagonist"
      },
      "correct_answer": "D",
      "explanation": "Correct Answer : D) M3 receptor antagonist Explanation: Ipratropium is an anticholinergic agent that works by blocking the M3 receptors on smooth muscle cells in the airways, leading to bronchodilation . It also inhibits the parasympathetic influence, which reduces bronchoconstriction and mucous secretion in the lungs, thereby improving airflow. M2 receptors are inhibitory receptors on presynaptic neurons that regulate acetylcholine release. While M2 antagonism can theoretically contribute to increased acetylcholine release, it is not the primary mechanism for ipratropium's therapeutic effect. Mechanism of Action Drug Mechanism of Action Effect Use Ipratropium M3 receptor antagonist Inhibition of parasympathetic tone, leading to bronchodilation COPD , asthma (often in combination with β 2 agonists) Albuterol β 2 receptor agonist Bronchodilation through smooth muscle relaxation Acute asthma , COPD relief Tiotropium M3 receptor antagonist Longer-acting bronchodilation COPD , asthma I 2 receptor agonist (Option A): Incorrect because albuterol is the β 2 receptor agonist , not ipratropium. It works by stimulating the β 2 receptors, leading to smooth muscle relaxation in the airways. M2 receptor agonist (Option B): Incorrect as M2 receptor agonism would typically inhibit the release of acetylcholine, which is not the mechanism of ipratropium. Ipratropium works by blocking M3 receptors on smooth muscle. M2 receptor antagonist (Option C): Incorrect because M2 receptor antagonism is not the primary mechanism of ipratropium. Ipratropium's effect is due to M3 receptor antagonism .",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Respiratory Pharmacology-Respiratory Pharmacology"
    },
    {
      "q_no": 14,
      "question": "A 30-year-old male with a history of asthma complains of wheezing, shortness of breath, and nighttime awakenings occurring about twice a week, with each episode lasting more than a day. His current medication regimen includes a SABA. Pulmonary function tests show a FEV1 of 70% predicted. Which is the most appropriate pharmacological management for this patient's condition?",
      "options": {
        "A": "Low-dose inhaled corticosteroids",
        "B": "High-dose inhaled corticosteroids",
        "C": "Long-acting beta-agonists and low-dose inhaled corticosteroids",
        "D": "Oral corticosteroids"
      },
      "correct_answer": "C",
      "explanation": "Correct Answer: C) Long-acting beta-agonists and low-dose inhaled corticosteroids Explanation: The above Clinical vignette suggests the presence of moderate persistent asthma in this patient. Categories of Asthma: Asthma classification Signs and symptoms Mild intermittent Mild symptoms up to 2 days a week and up to 2 nights a month Mild persistent Symptoms >2 times a week but not >1 time in a single day Moderate persistent Symptoms every day and >1 time/ week at night Severe persistent Symptoms throughout the day on most days and also frequent awakenings at night Step-up therapy for Chronic/Persistent asthma: Reference: KD Tripathi Essentials of Medical Pharmacology, 8th Edition, Page 253 https://www.mayoclinic.org/diseases-conditions/asthma/diagnosis-treatment/drc-20369660 https://tmedweb.tulane.edu/pharmwiki/doku.php/",
      "image": null,
      "explanation_image": "https://raw.githubusercontent.com/tk22kalal/mcqimage/main/pxpharmacology/Respiratory_Pharmacology-Respiratory_Pharmacology_Q14_exp.jpg",
      "chapter_heading": "Respiratory Pharmacology-Respiratory Pharmacology"
    },
    {
      "q_no": 15,
      "question": "A 25-year-old asthmatic presents with severe respiratory distress and is unresponsive to her albuterol inhaler. She has a respiratory rate of 32, oxygen saturation of 88%, and audible wheezing. Initial treatment with high-dose nebulized albuterol and systemic corticosteroids has shown only minimal improvement. What is the most appropriate next step in managing her condition?",
      "options": {
        "A": "Repeat",
        "B": "Aminophylline",
        "C": "Ipratropium",
        "D": "Magnesium sulfate"
      },
      "correct_answer": "D",
      "explanation": "Correct Answer : D) Magnesium sulfate Explanation : The above Clinical scenario suggests a classic presentation of Status asthmaticus. Status asthmaticus : Defined as severe asthma that does not respond to repeated beta-agonist treatments (inhaled albuterol, levalbuterol, or subcutaneous epinephrine) Considered a medical emergency Requires immediate recognition and treatment Management : Reference: https://www.ncbi.nlm.nih.gov/books/NBK526070/ https://pubmed.ncbi.nlm.nih.gov/22794687/",
      "image": null,
      "explanation_image": "https://raw.githubusercontent.com/tk22kalal/mcqimage/main/pxpharmacology/Respiratory_Pharmacology-Respiratory_Pharmacology_Q15_exp.jpg",
      "chapter_heading": "Respiratory Pharmacology-Respiratory Pharmacology"
    },
    {
      "q_no": 16,
      "question": "A 24-year-old male presents with shortness of breath, wheezing, and chest tightness. He has a known history of asthma. On examination, he appears distressed, with an RR of 30/min, HR of 110/min, and a SpO2 of 92% on room air. Auscultation reveals widespread wheezing. Which of the following is the most appropriate initial pharmacological management for this presentation?",
      "options": {
        "A": "Oral Prednisone 40 mg",
        "B": "Inhaled Salbutamol 2.5 mg via nebulizer",
        "C": "Inhaled Fluticasone 100 mcg",
        "D": "Montelukast 10 mg orally"
      },
      "correct_answer": "B",
      "explanation": "Correct Answer: B) Inhaled Salbutamol 2.5 mg via nebuliser Explanation: In the management of an acute asthma exacerbation , the first-line treatment is a short-acting beta-agonist (SABA) such as salbutamol (albuterol). This medication works to relax bronchial smooth muscle, leading to rapid improvement in airway obstruction and relief of symptoms. It acts as quickly as 5 minutes within the administration, and the effect lasts for around 2-4 hours. Oral corticosteroids (eg. prednisolone) (Option A) are not the first-line treatment for immediate relief of symptoms, instead they are typically given after initial stabilization with a SABA. Inhaled corticosteroids (eg. fluticasone) and leukotriene receptor antagonists (eg. montelukast) (Options C & D ) are used for long-term management and prevention of asthma symptoms and are not effective for immediate relief in an acute exacerbation. Reference: KDT-Essentials of Medical Pharmacology, 8th Edition, Page 242. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2817338/",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Respiratory Pharmacology-Respiratory Pharmacology"
    },
    {
      "q_no": 17,
      "question": "A 42-year-old female patient with a history of severe asthma presents with frequent exacerbations despite being on corticosteroids. She is about to get started on omalizumab. Which of the following mechanisms best describes the action of omalizumab?",
      "options": {
        "A": "Inhibiting leukotriene synthesis",
        "B": "Blocking the activity of TNF-alpha",
        "C": "Neutralizing free IgE in circulation",
        "D": "Suppressing eosinophil activation"
      },
      "correct_answer": "C",
      "explanation": "Correct Answer: C) Neutralizing free IgE in circulation Explanation : Omalizumab is a humanized monoclonal antibody that binds to circulating free IgE . By binding to the Fc portion of IgE , omalizumab prevents IgE from interacting with Fc ε RI receptors on mast cells and basophils. This inhibits the allergic cascade , reducing the frequency and severity of asthma exacerbations in patients with allergic asthma . Mechanism and Use of Omalizumab Feature Details Type Recombinant humanized monoclonal antibody Target Free IgE in the bloodstream Mechanism Binds to IgE → prevents binding to Fc ε RI on mast cells and basophils Result Decreased allergen-induced mast cell degranulation Indications Moderate-to-severe allergic asthma , chronic urticaria Administration Subcutaneous injection every 2–4 weeks Notable Adverse Effects Injection site reactions, anaphylaxis (rare), headache Anti-inflammatory drugs in Asthma : Inhibiting leukotriene synthesis (Option A): Incorrect. This is the mechanism of zileuton , a 5-lipoxygenase inhibitor, not omalizumab. Blocking the activity of TNF-alpha (Option B): Incorrect. This is the mechanism of agents like infliximab or etanercept , used in autoimmune diseases, not asthma. Suppressing eosinophil activation (Option D): Incorrect. Suppression of eosinophils is the mechanism of mepolizumab or benralizumab , not omalizumab.",
      "image": null,
      "explanation_image": "https://raw.githubusercontent.com/tk22kalal/mcqimage/main/pxpharmacology/Respiratory_Pharmacology-Respiratory_Pharmacology_Q17_exp.png",
      "chapter_heading": "Respiratory Pharmacology-Respiratory Pharmacology"
    },
    {
      "q_no": 18,
      "question": "A 12-year-old female patient with cystic fibrosis (CF) presents to the clinic with increased cough and thick sputum production, causing shortness of breath and fatigue. Which of the following medications would be the most effective for this patient?",
      "options": {
        "A": "Pancrelipase",
        "B": "Dornase alfa",
        "C": "Cevimeline",
        "D": "Lumacaftor"
      },
      "correct_answer": "B",
      "explanation": "Correct Answer: B) Dornase alfa Explanation: Dornase alfa is an enzyme that reduces mucus viscosity by cleaving extracellular DNA in the airway secretions. Management of Cystic fibrosis: Symptom Treatment Dry eyes, mouth (Xerophthalmia, xerostomia) Pilocarpine Cevimeline (Option C) Hard mucus Mucolytics - N acetylcysteine Erdosteine Carbocysteine Dornase alpha (Degrades DNA) Hypertonic saline Recurrent pneumonia (Pseudomonas) Inhalational antibiotics - Tobramycin Amikacin Colistin Aztreonam Chronic pancreatitis Pancreatic enzyme replacement (Pancrezyme) Disease-modifying therapy Lumacaftor (Option D) Ivacaftor Elexacaftor Pancrelipase (Option A) is a pancreatic enzyme replacement therapy to aid digestion. Reference: Goodman and Gilman's The Pharmacological Basis of Therapeutics, 14th Edition Page 892",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Respiratory Pharmacology-Respiratory Pharmacology"
    },
    {
      "q_no": 19,
      "question": "A 30-year-old female presented with complaints of a persistent dry cough for the past week and an antitussive was prescribed. Two days later, the patient returned with nausea, vomiting, and constipation. Which centrally acting antitussive medication is most likely responsible for these adverse effects in this patient?",
      "options": {
        "A": "Codeine",
        "B": "Dextromethorphan",
        "C": "Noscapine",
        "D": "Promethazine"
      },
      "correct_answer": "A",
      "explanation": "Correct Answer: A) Codeine Explanation: The patient presents with symptoms suggestive of codeine-induced adverse effects, including nausea, vomiting, and constipation. Opioids commonly cause gastrointestinal adverse effects due to agonistic activity on their receptors in the gastrointestinal tract. Dextromethorphan (Option B), noscapine (Option C) and promethazine (Option D) are less likely to cause gastrointestinal adverse effects compared to codeine. Centrally acting Antitussives: Class Drugs Mechanism Adverse effects Opioids Morphine Hydromorphone Oxymorphone Codeine Hydrocodone Oxycodone Pholcodine Suppress cough centre Codeine - Constipation Respiratory depression Drowsiness Non Opioids Dextromethorphan Noscapine Dextromethorphan- Acts on glutamate receptor-NMDA antagonist. Noscapine-Sigma agonist Dextromethorphan- Dizziness Nausea Drowsiness At high doses- Hallucinations Ataxia Antihistaminic drugs Cetirizine Promethazine H1 receptor antagonists Drowsiness Sedation Somnolence Fatigue Headache Reference: KD Tripathi Essentials of Medical Pharmacology, 8th Edition, Page 239",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Respiratory Pharmacology-Respiratory Pharmacology"
    }
  ]
}
